Table 3 Clinical characteristics and endocrine treatment history in patients with confirmed ESR1 E380Q mutant ttDNA
From: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
Clinical Characteristics | Before mutation analysis | After mutation analysis | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CT | ET | CT | ET | ||||||||||||
ID | Metastatic ER (%) | Detected ESR1 mut | ESR1 mut MAFs (%) | Stage at diagnosis | Adjuvant ET | Adjuvant ET Duration (Months) | DFI (Months) | No. of therapies | No. of therapies | Cumulative Exposure (Months) | Type of ET | No. of therapies | No. of therapies | Cumulative Exposure (Months) | Type of ET |
M43 a | 70 | E380Q | 21.7 | I | SERM | 16 | 16 | 5 | Adjuvant only | No | No | No | No | ||
M50 a | 80 | Y537S/ E380Q | 12.8/2.69 | I | LHRHa, SERM | 48 | 72 | 4 | 4 | 40 | LHRHa, SERM, AI | 1 | 1 | 2 | AI |